NAPA, Calif.—A specialty compound from Senetek PLC appears to offer home to rosacea sufferers, based on clinical study results presented at the 7th Annual South Beach Clinical Dermatology Symposium, held in mid-February in Miami. In a 48-week trial, 18 adults with mild-to-moderate rosacea were given Pyratine-XR™ (0.125% furfuryl tetrahydropyranyladenine) and evaluated by physicians for inflammatory lesions, severity of erythema (redness) and spider veins. Patients also assessed their signs and symptoms and skin tolerance.
After the trial, 80 percent of subjects had overall clinical improvement in rosacea symptoms, particularly a reduction in erythema and lesions. Pyratine-XR treatment resulted in a 90 percent improvement in lesions, 45 percent improvement in erythema and 28 percent improvement in spider veins. The product was also well tolerated.
Frank J. Massino, chairman and CEO of Senetek, said: “We are incredibly pleased with the results reported in this rosacea-specific study, with continual improvement in lesions, redness and spider veins. Unlike current therapies, Pyratine-XR™ was well tolerated by all patients, and offers hope to a myriad of individuals suffering from facial redness, acne lesions and spider veins, such as those afflicted with eczema, atopic dermatitis and rosacea.